Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. 

Biotechnology

Research

Switch Therapeutics

Dee Datta

Shilpi Mahajan

Anindya Bhattacharya

Maxine Nelson

Clara Tourino

Joonhee Han

Alex Embusch

Marina Kovaliov

Jane Li

Robert Duff

Don Button

Craig Blanchette

Michael Wolfe

The Research and Development team at Switch Therapeutics is dedicated to advancing the CASi platform by conducting cutting-edge research in RNA discovery, medicinal chemistry, and biology. This multidisciplinary team collaborates on the design, synthesis, and evaluation of novel RNA-based therapeutics, aiming to harness the potential of nucleic acid nanotechnology to address challenging diseases of the central nervous system and other systemic indications. Their efforts focus on translating innovative scientific insights into effective treatment solutions with a strong emphasis on project management and bioanalytics.

Research and Development

Leadership Team

Research Associates

Research and Development

About

Team members

Other teams at Switch Therapeutics

Leadership Team

Research Associates